Vascular α-adrenoceptors: From the gene to the human

D. B. Bylund, J. W. Regan, J. E. Faber, J. P. Hieble, Christopher Triggle, R. R. Ruffolo

Research output: Contribution to journalArticle

55 Citations (Scopus)

Abstract

Adrenoceptors can be subdivided into three major types, the α1-, α2-, and β-adrenoceptors. Each of these types can be further subdivided into three subtypes, based on pharmacological characteristics. Molecular cloning techniques have supported this subclassification. Recent data now suggest that α-adrenoceptor subtypes identified by pharmacological and molecular techniques correspond well, although species orthologs of several adrenoceptor subtypes have been identified. The secondary structure of the adrenoceptors has been elucidated and correlated with their interaction with second messenger molecules. α1-Adrenoceptors, β-adrenoceptors, and α2-adrenoceptors mediate their actions through stimulation of inositol phosphate release, stimulation of adenylate cyclase, and inhibition of adenylate cyclase, respectively. Site-directed mutagenesis and the preparation of chimeric receptors have located the site of receptor-second messenger interaction to the third intracellular loop for each of these adrenoceptors. While subtypes of each of these classes all interact with the same second messenger, studies with recombinant α2-adrenoceptors show subtype-related differences in receptor-second messenger interaction. Multiple α-adrenoceptor subtypes are expressed in vascular smooth muscle and are involved in various aspects of blood vessel function, including contraction, cellular growth, and proliferation. Various physiological factors can selectively influence responses to a particular subtype, and the relative roles of each subtype can vary between vascular beds and along an individual blood vessel as its caliber changes. Functional studies in blood vessels suggest the presence of additional α-adrenoceptor subtypes not yet identified via molecular techniques. Optimization of the therapeutic profile of an α-adrenoceptor antagonist may be possible via enhancement of selectivity for a particular subtype or by design of a specific profile of affinity for the individual subtypes.

Original languageEnglish
Pages (from-to)533-543
Number of pages11
JournalCanadian Journal of Physiology and Pharmacology
Volume73
Issue number5
Publication statusPublished - 1995
Externally publishedYes

Fingerprint

Adrenergic Receptors
Blood Vessels
Genes
Second Messenger Systems
Adenylyl Cyclases
Pharmacology
Inositol Phosphates
Molecular Cloning
Site-Directed Mutagenesis
Vascular Smooth Muscle
Cell Proliferation

Keywords

  • adrenoceptor subclassification
  • G-proteins
  • second messenger
  • smooth muscle proliferation
  • vasoconstriction

ASJC Scopus subject areas

  • Physiology
  • Pharmacology

Cite this

Bylund, D. B., Regan, J. W., Faber, J. E., Hieble, J. P., Triggle, C., & Ruffolo, R. R. (1995). Vascular α-adrenoceptors: From the gene to the human. Canadian Journal of Physiology and Pharmacology, 73(5), 533-543.

Vascular α-adrenoceptors : From the gene to the human. / Bylund, D. B.; Regan, J. W.; Faber, J. E.; Hieble, J. P.; Triggle, Christopher; Ruffolo, R. R.

In: Canadian Journal of Physiology and Pharmacology, Vol. 73, No. 5, 1995, p. 533-543.

Research output: Contribution to journalArticle

Bylund, DB, Regan, JW, Faber, JE, Hieble, JP, Triggle, C & Ruffolo, RR 1995, 'Vascular α-adrenoceptors: From the gene to the human', Canadian Journal of Physiology and Pharmacology, vol. 73, no. 5, pp. 533-543.
Bylund DB, Regan JW, Faber JE, Hieble JP, Triggle C, Ruffolo RR. Vascular α-adrenoceptors: From the gene to the human. Canadian Journal of Physiology and Pharmacology. 1995;73(5):533-543.
Bylund, D. B. ; Regan, J. W. ; Faber, J. E. ; Hieble, J. P. ; Triggle, Christopher ; Ruffolo, R. R. / Vascular α-adrenoceptors : From the gene to the human. In: Canadian Journal of Physiology and Pharmacology. 1995 ; Vol. 73, No. 5. pp. 533-543.
@article{86b64ce598ee48768e8254885b133b99,
title = "Vascular α-adrenoceptors: From the gene to the human",
abstract = "Adrenoceptors can be subdivided into three major types, the α1-, α2-, and β-adrenoceptors. Each of these types can be further subdivided into three subtypes, based on pharmacological characteristics. Molecular cloning techniques have supported this subclassification. Recent data now suggest that α-adrenoceptor subtypes identified by pharmacological and molecular techniques correspond well, although species orthologs of several adrenoceptor subtypes have been identified. The secondary structure of the adrenoceptors has been elucidated and correlated with their interaction with second messenger molecules. α1-Adrenoceptors, β-adrenoceptors, and α2-adrenoceptors mediate their actions through stimulation of inositol phosphate release, stimulation of adenylate cyclase, and inhibition of adenylate cyclase, respectively. Site-directed mutagenesis and the preparation of chimeric receptors have located the site of receptor-second messenger interaction to the third intracellular loop for each of these adrenoceptors. While subtypes of each of these classes all interact with the same second messenger, studies with recombinant α2-adrenoceptors show subtype-related differences in receptor-second messenger interaction. Multiple α-adrenoceptor subtypes are expressed in vascular smooth muscle and are involved in various aspects of blood vessel function, including contraction, cellular growth, and proliferation. Various physiological factors can selectively influence responses to a particular subtype, and the relative roles of each subtype can vary between vascular beds and along an individual blood vessel as its caliber changes. Functional studies in blood vessels suggest the presence of additional α-adrenoceptor subtypes not yet identified via molecular techniques. Optimization of the therapeutic profile of an α-adrenoceptor antagonist may be possible via enhancement of selectivity for a particular subtype or by design of a specific profile of affinity for the individual subtypes.",
keywords = "adrenoceptor subclassification, G-proteins, second messenger, smooth muscle proliferation, vasoconstriction",
author = "Bylund, {D. B.} and Regan, {J. W.} and Faber, {J. E.} and Hieble, {J. P.} and Christopher Triggle and Ruffolo, {R. R.}",
year = "1995",
language = "English",
volume = "73",
pages = "533--543",
journal = "Canadian Journal of Physiology and Pharmacology",
issn = "0008-4212",
publisher = "National Research Council of Canada",
number = "5",

}

TY - JOUR

T1 - Vascular α-adrenoceptors

T2 - From the gene to the human

AU - Bylund, D. B.

AU - Regan, J. W.

AU - Faber, J. E.

AU - Hieble, J. P.

AU - Triggle, Christopher

AU - Ruffolo, R. R.

PY - 1995

Y1 - 1995

N2 - Adrenoceptors can be subdivided into three major types, the α1-, α2-, and β-adrenoceptors. Each of these types can be further subdivided into three subtypes, based on pharmacological characteristics. Molecular cloning techniques have supported this subclassification. Recent data now suggest that α-adrenoceptor subtypes identified by pharmacological and molecular techniques correspond well, although species orthologs of several adrenoceptor subtypes have been identified. The secondary structure of the adrenoceptors has been elucidated and correlated with their interaction with second messenger molecules. α1-Adrenoceptors, β-adrenoceptors, and α2-adrenoceptors mediate their actions through stimulation of inositol phosphate release, stimulation of adenylate cyclase, and inhibition of adenylate cyclase, respectively. Site-directed mutagenesis and the preparation of chimeric receptors have located the site of receptor-second messenger interaction to the third intracellular loop for each of these adrenoceptors. While subtypes of each of these classes all interact with the same second messenger, studies with recombinant α2-adrenoceptors show subtype-related differences in receptor-second messenger interaction. Multiple α-adrenoceptor subtypes are expressed in vascular smooth muscle and are involved in various aspects of blood vessel function, including contraction, cellular growth, and proliferation. Various physiological factors can selectively influence responses to a particular subtype, and the relative roles of each subtype can vary between vascular beds and along an individual blood vessel as its caliber changes. Functional studies in blood vessels suggest the presence of additional α-adrenoceptor subtypes not yet identified via molecular techniques. Optimization of the therapeutic profile of an α-adrenoceptor antagonist may be possible via enhancement of selectivity for a particular subtype or by design of a specific profile of affinity for the individual subtypes.

AB - Adrenoceptors can be subdivided into three major types, the α1-, α2-, and β-adrenoceptors. Each of these types can be further subdivided into three subtypes, based on pharmacological characteristics. Molecular cloning techniques have supported this subclassification. Recent data now suggest that α-adrenoceptor subtypes identified by pharmacological and molecular techniques correspond well, although species orthologs of several adrenoceptor subtypes have been identified. The secondary structure of the adrenoceptors has been elucidated and correlated with their interaction with second messenger molecules. α1-Adrenoceptors, β-adrenoceptors, and α2-adrenoceptors mediate their actions through stimulation of inositol phosphate release, stimulation of adenylate cyclase, and inhibition of adenylate cyclase, respectively. Site-directed mutagenesis and the preparation of chimeric receptors have located the site of receptor-second messenger interaction to the third intracellular loop for each of these adrenoceptors. While subtypes of each of these classes all interact with the same second messenger, studies with recombinant α2-adrenoceptors show subtype-related differences in receptor-second messenger interaction. Multiple α-adrenoceptor subtypes are expressed in vascular smooth muscle and are involved in various aspects of blood vessel function, including contraction, cellular growth, and proliferation. Various physiological factors can selectively influence responses to a particular subtype, and the relative roles of each subtype can vary between vascular beds and along an individual blood vessel as its caliber changes. Functional studies in blood vessels suggest the presence of additional α-adrenoceptor subtypes not yet identified via molecular techniques. Optimization of the therapeutic profile of an α-adrenoceptor antagonist may be possible via enhancement of selectivity for a particular subtype or by design of a specific profile of affinity for the individual subtypes.

KW - adrenoceptor subclassification

KW - G-proteins

KW - second messenger

KW - smooth muscle proliferation

KW - vasoconstriction

UR - http://www.scopus.com/inward/record.url?scp=0029123209&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0029123209&partnerID=8YFLogxK

M3 - Article

C2 - 7585318

AN - SCOPUS:0029123209

VL - 73

SP - 533

EP - 543

JO - Canadian Journal of Physiology and Pharmacology

JF - Canadian Journal of Physiology and Pharmacology

SN - 0008-4212

IS - 5

ER -